View in EDS

Disease progression is associated with differential neutrophil maturation in Mycobacterium tuberculosis-infected macaques.

Saved in:
Bibliographic Details
Title: Disease progression is associated with differential neutrophil maturation in Mycobacterium tuberculosis-infected macaques.
Authors: Dinko S; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Joly C; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Mazet P; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Sandillon G; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Magneron V; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Nunez N; Life and Soft, A SeqOne Company, Montpellier, France., Mayet C; Life and Soft, A SeqOne Company, Montpellier, France., Diry S; Life and Soft, A SeqOne Company, Montpellier, France., Gaspar C; Life and Soft, A SeqOne Company, Montpellier, France., Leonec M; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Luccantoni S; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Ludot C; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Delache B; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Jougla E; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Morin J; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Zouaoui-Frigui W; Unit for Integrated Mycobacterial Pathogenomics, Institut Pasteur, Université Paris Cité, Paris, France., Brosch R; Unit for Integrated Mycobacterial Pathogenomics, Institut Pasteur, Université Paris Cité, Paris, France., Contreras V; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Galloüet AS; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Bosquet N; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Relouzat F; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Pascal Q; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Jean B; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Holzapfel M; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Lambotte O; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Naninck T; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Le Grand R; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Lemaitre J; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Université Paris-Saclay - Inserm - CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Source: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2026 Jun 07; Vol. 215 (6).
Publication Type: Journal Article
Journal Info: Publisher: American Association of Immunologists Country of Publication: England NLM ID: 2985117R Publication Model: Print Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1550-6606
DOI:10.1093/jimmun/vkag114